Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galien et al.

Maurer M. J.; Habermann T. M.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galien et al.

【24h】

Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galien et al.

机译：在24个月（PFS24）和随后的24个月内答复到编辑的无进展生存，并通过Van der Galien等，对现实世界的衍射大B细胞淋巴瘤（DLBCL）的患者进行后续结果。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2019年第1期|共1页
作者
Maurer M. J.; Habermann T. M.;
展开▼
作者单位

Mayo Clin Dept Hlth Sci Res Rochester MN 33124 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galien et al. [J] . Maurer M. J., Habermann T. M. Annals of oncology: official journal of the European Society for Medical Oncology . 2019,第1期

机译：在24个月（PFS24）和随后的24个月内答复到编辑的无进展生存，并通过Van der Galien等，对现实世界的衍射大B细胞淋巴瘤（DLBCL）的患者进行后续结果。
2. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting [J] . van der Galien H. T., Hoogendoorn M., Kibbelaar R. E., Annals of oncology: official journal of the European Society for Medical Oncology . 2019,第1期

机译：24个月（PFS24）的无进展生存和随后的衍射大B细胞淋巴瘤（DLBCL）的患者的后续结果
3. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials [J] . Maurer M. J., Habermann T. M., Shi Q., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第8期

机译：24个月（PFS24）的无进展生存率和随后的弥漫性大B细胞淋巴瘤（DLBCL）患者的后续结果纳入随机临床试验
4. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials [O] . M J Maurer, T M Habermann, Q Shi, -1

机译：随机临床试验纳入了弥漫性大B细胞淋巴瘤（DLBCL）患者的24个月无进展生存期（PFS24）及其后续结果
5. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials [O] . M.J. Maurer, T.M. Habermann, Q. Shi, 2018

机译：24个月（PFS24）的无进展生存率和随后的弥漫性大B细胞淋巴瘤（DLBCL）患者的后续结果纳入随机临床试验

Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galien et al.

著录项

相似文献

相关主题

期刊订阅